|
|
Article: Investors Like Reports on Immune Response.(Brief Article)(Statistical Data Included)
- Article from:
- San Diego Business Journal
- Article date:
- April 30, 2001
- Author:
CopyrightCOPYRIGHT 2001 CBJ, L.P. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
It was as if Immune Response Corp. awakened from the dead. After months of no news, following bad news, the Carlsbad-based biotechnology company made headlines of a stock resurgence.
Shares of Immune Response climbed as much as 115 percent April 23, the day the firm announced a European medical journal will publish a detailed analysis of a subset of data that suggests its experimental AIDS vaccine, Remune, benefits some patients.
Company shares closed at $2.58 on April 23, up 95 cents from April 20.
Investors' excitement, however, was short-lived.
Immune Response shares dropped to $2.18 on April 24 and closed at $2.05 the next day.
...